Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. Hamilton E, et al. Among authors: hernando c. Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8. Ann Oncol. 2024. PMID: 38729567 Free article. Clinical Trial.
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J. Pernas S, et al. Among authors: hernando c. Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26. Lancet Oncol. 2018. PMID: 29706375 Clinical Trial.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J. Prat A, et al. Among authors: hernando c. Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838010 Clinical Trial.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
Pascual T, Fernandez-Martinez A, Agrawal Y, Pfefferle AD, Chic N, Brasó-Maristany F, Gonzàlez-Farré B, Paré L, Villacampa G, Saura C, Hernando C, Muñoz M, Galván P, Gonzàlez-Farré X, Oliveira M, Gil-Gil M, Ciruelos E, Villagrasa P, Gavilá J, Prat A, Perou CM. Pascual T, et al. Among authors: hernando c. NPJ Breast Cancer. 2024 Mar 6;10(1):20. doi: 10.1038/s41523-024-00625-7. NPJ Breast Cancer. 2024. PMID: 38448600 Free PMC article.
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Villacampa G, Falato C, Paré L, Hernando C, Arumí M, Saura C, Gómez G, Muñoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Najera-Zuloaga J, Montaño A, Ciruelos E, González-Santiago S, Villagrasa P, Gavilá J, Prat A, Pascual T. Villacampa G, et al. Among authors: hernando c. Eur J Cancer. 2022 Oct;174:232-242. doi: 10.1016/j.ejca.2022.07.028. Epub 2022 Sep 5. Eur J Cancer. 2022. PMID: 36067616 Clinical Trial.
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Manso L, Hernando C, Galán M, Oliveira M, Cabrera MA, Bratos R, Rodríguez CA, Ruiz-Borrego M, Blanch S, Llombart-Cussac A, Delgado-Mingorance JI, Álvarez-Busto I, Gallegos I, González-Cortijo L, Morales S, Aguirre E, Hernando BA, Ballesteros A, Alés-Martínez JE, Reboredo C, Oltra A, González-Cao M, Santisteban M, Malón D, Echeverría I, García-Garre E, Vega E, Servitja S, Andrés R, Robles CE, López R, Galve E, Echarri MJ, Legeren M, Moreno F. Manso L, et al. Among authors: hernando c, hernando ba. Breast. 2020 Dec;54:286-292. doi: 10.1016/j.breast.2020.11.005. Epub 2020 Nov 13. Breast. 2020. PMID: 33242755 Free PMC article.
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.
Oltra SS, Cejalvo JM, Tormo E, Albanell M, Ferrer A, Nacher M, Bermejo B, Hernando C, Chirivella I, Alonso E, Burgués O, Peña-Chilet M, Eroles P, Lluch A, Ribas G, Martinez MT. Oltra SS, et al. Among authors: hernando c. Cancers (Basel). 2020 Feb 10;12(2):412. doi: 10.3390/cancers12020412. Cancers (Basel). 2020. PMID: 32050699 Free PMC article.
Immunological Landscape of HER-2 Positive Breast Cancer.
Moragon S, Hernando C, Martinez-Martinez MT, Tapia M, Ortega-Morillo B, Lluch A, Bermejo B, Cejalvo JM. Moragon S, et al. Among authors: hernando c. Cancers (Basel). 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167. Cancers (Basel). 2022. PMID: 35804943 Free PMC article. Review.
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Tapia M, et al. Among authors: hernando c. Cancers (Basel). 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522. Cancers (Basel). 2023. PMID: 37760491 Free PMC article. Review.
120 results